Bayer welcomes today’s decision by the Court as it is in line with the science-based profile of the safety and efficacy of Essure, a permanent contraceptive device for women.

Bayer stands behind the safety and efficacy profiles of Essure, which is supported by an extensive body of research (including 10 clinical trials and over 150 studies, undertaken by Bayer and independent medical researchers, involving more than 280,000 women over the past two decades).

The health and wellbeing of women who rely on our products is our greatest priority. Women who currently have Essure may continue to confidently rely on the device. If a woman with Essure has questions or concerns about the device, then we encourage her to speak to her healthcare professional.